Clinical trials: Refractory B-Cell Non-Hodgkin Lymphoma
Leukemia, Lymphoma
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00014560
- Testing
- bispecific antibody 4G7xH22, sargramostim
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Diffuse Large Cell Lymphoma Relapsed/Refractory
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell…
- Trial name
- NCT01555541
- Testing
- Ofatumumab, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- C. Babis Andreadis
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Hodgkin's Lymphoma
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
ATHENA chimeric antigen receptor (CAR)-T, a CD19-directed CAR-T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT06014073
- Testing
- TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Cyclophosphamide
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
B-Cell Leukemia, B-Cell Lymphoma
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+…
- Conditions
- B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors
- Trial name
- NCT05932173
- Testing
- Anti-CD19 Autologous CAR-T Cell Infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Diffuse, Large B-Cell, Lymphoma
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a…
- Trial name
- NCT02391116
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 32 sites in Australia, Belgium and 8 more
- Volunteers
- 67 people
- Sponsor
- Bayer
Diffuse Large B-cell Lymphoma
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.
- Trial name
- PRO-R-IPI (NCT01369784)
- Where
- 56 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
- Trial name
- CAR19T2 (NCT05613348)
- Testing
- CD19 CAR T-Cell(CAT19T2)
- Where
- 2 sites in China
- Sponsor
- Zhujiang Hospital
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Lymphoma
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00244985
- Testing
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Large B-cell Lymphoma, Lymphoma, B-Cell
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma…
- Conditions
- Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Trial name
- PiNACLE-H2H (NCT07188558)
- Testing
- rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
- Where
- 44 sites in United States, Australia and 1 more
- Volunteers
- 400 people
- Sponsor
- Lyell Immunopharma, Inc.
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (R/R) follicular lymphoma (FL) and…
- Trial name
- NCT02600897
- Testing
- Lenalidomide, Obinutuzumab, Polatuzumab Vedotin
- Where
- 28 sites in United States, Spain and 1 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be…
- Trial name
- ILIAD (NCT03576443)
- Testing
- Idelalisib
- Where
- 6 sites in Denmark, Sweden
- Volunteers
- 36 people
- Sponsor
- Nordic Lymphoma Group
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation.
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06247540
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Sponsor
- Northwestern University
Non Hodgkin Lymphoma
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
- Trial name
- TIGER-CTL019 (NCT04161118)
- Testing
- CTL019
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- University of Cologne
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01799889
- Testing
- Entospletinib MM, Entospletinib SDD
- Where
- 48 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- Gilead Sciences
B-Cell Acute Lymphoblastic Leukemia
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT07429461
- Testing
- SYNCAR-100 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Non-hodgkin Lymphoma,B Cell
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
- Trial name
- NCT05741359
- Testing
- CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.